Abstract | OBJECTIVES/INTRODUCTION: Herein we review the evidence supporting Food and Drug Administration (FDA) approved and emerging treatments for bipolar depression. METHODS: A PubMed search of all English-language articles published up to July 2013 was conducted. The search terms were quetiapine, olanzapine- fluoxetine, olanzapine, lurasidone, ketamine, modafinil/ armodafinil, and lamotrigine. The search was augmented with a manual review of relevant article reference lists, as well as posters presented at national and international meetings. Articles selected for review were based on the adequacy of sample size, the use of standardized diagnostic instruments, validated assessment measures, and overall manuscript quality. RESULTS: CONCLUSION: Relatively few agents are FDA-approved for bipolar depression. The selection and sequencing of agents in bipolar depression should give primacy to those agents that are FDA-approved. Further refinement of the selection process will need to pay careful attention to the relative hazards of weight gain and metabolic disruption in this highly susceptible population. Other agents with differential mechanisms (eg, ketamine) offer a promising alternative in bipolar depression.
|
Authors | Roger S McIntyre, Danielle S Cha, Rachael D Kim, Rodrigo B Mansur |
Journal | CNS spectrums
(CNS Spectr)
Vol. 18 Suppl 1
Pg. 4-20; quiz 21
(Dec 2013)
ISSN: 1092-8529 [Print] United States |
PMID | 24237641
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antidepressive Agents
- Antidepressive Agents, Second-Generation
- Antipsychotic Agents
- Benzhydryl Compounds
- Central Nervous System Stimulants
- Dibenzothiazepines
- Drug Combinations
- Excitatory Amino Acid Antagonists
- Isoindoles
- Serotonin Uptake Inhibitors
- Thiazoles
- Triazines
- olanzapine-fluoxetine combination
- Fluoxetine
- Benzodiazepines
- Quetiapine Fumarate
- Ketamine
- Lurasidone Hydrochloride
- Modafinil
- Lamotrigine
|
Topics |
- Antidepressive Agents
(therapeutic use)
- Antidepressive Agents, Second-Generation
(therapeutic use)
- Antipsychotic Agents
(therapeutic use)
- Benzhydryl Compounds
(therapeutic use)
- Benzodiazepines
(therapeutic use)
- Bipolar Disorder
(drug therapy)
- Central Nervous System Stimulants
(therapeutic use)
- Depressive Disorder
(drug therapy)
- Dibenzothiazepines
(therapeutic use)
- Drug Approval
- Drug Combinations
- Excitatory Amino Acid Antagonists
(therapeutic use)
- Fluoxetine
(therapeutic use)
- Humans
- Isoindoles
(therapeutic use)
- Ketamine
(therapeutic use)
- Lamotrigine
- Lurasidone Hydrochloride
- Modafinil
- Quetiapine Fumarate
- Selective Serotonin Reuptake Inhibitors
(therapeutic use)
- Thiazoles
(therapeutic use)
- Triazines
(therapeutic use)
- United States
- United States Food and Drug Administration
|